English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/115653
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon-β treatment

AuthorsMalhotra, Sunny; Morcillo-Suárez, Carlos ; Navarro, Arcadi ; Comabella, Manuel
KeywordsInterferon-β
Multiple sclerosis
Response to treatment
USP18 polymorphisms
Genetic susceptibility
Issue DateOct-2013
PublisherJohn Wiley & Sons
CitationEuropean Journal of Neurology 20(10): 1390-1397 (2013)
Abstract[Background and purpose] Ubiquitin specific peptidase 18 (USP18) is a deubiquitinating enzyme that functions as a negative regulator of the type I interferon (IFN) signalling pathway and is specifically induced by type I IFNs. In the present study, previous observations by our group were expanded suggesting an implication of USP18 in multiple sclerosis (MS) based on the finding of a deficient expression of the gene in peripheral blood mononuclear cells from MS patients compared with healthy controls. [Methods] Two polymorphisms, rs2542109 (intronic) and rs9618216 (promoter), were genotyped in a cohort of 691 relapse-onset MS patients and 1028 healthy controls and in 225 MS patients treated with IFNβ and classified into responders and non-responders after 2 years of treatment according to clinical criteria. Correlations between genotypes and expression levels for USP18 and its target ISG15 were performed by real-time polymerase chain reaction. [Results] Two USP18 haplotypes were significantly associated with MS, TG and CG. Additional experiments revealed that CG carriers were characterized by lower USP18 gene expression levels in peripheral blood mononuclear cells and higher clinical disease activity. Finally, AA homozygosis for the intronic polymorphism rs2542109 was associated with the responder phenotype; however, USP18 expression levels induced by IFNβ did not differ amongst MS patients carrying different rs2542109 genotypes. [Conclusions] Altogether, these results point to a role of USP18 in MS pathogenesis and the therapeutic response to IFNβ. © 2013 EFNS.
DescriptionMalhotra, Sunny et al.
Publisher version (URL)http://dx.doi.org/10.1111/ene.12193
URIhttp://hdl.handle.net/10261/115653
DOI10.1111/ene.12193
Identifiersdoi: 10.1111/ene.12193
issn: 1351-5101
e-issn: 1468-1331
Appears in Collections:(IBE) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.